AsianScientist (Mar. 13, 2012) – OriGene Technologies, Inc. has announced the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio).
Headquartered in Beijing, China since 1993, ZsBio provides pathology testing products to the growing Chinese oncology diagnostic market, which has experienced double-digit growth annually and is one of the fast-growing segments of the Chinese diagnostic industry.
The strategic acquisition is set to establish OriGene’s leading position in the Chinese pathology testing market.
“With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene,” said Wei-Wu He, CEO of OriGene.
“ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative highly specific monoclonal antibodies and assays to complement and strengthen ZsBio’s portfolio of products.”
——
Source: OriGene Technologies, Inc.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
